Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

Inclusion criteria

• Signed IRB approved written informed consent/assent
• 12 to 75 years of age, inclusive.
• Subjects must have a clinical diagnosis of stable symptomatic plaque psoriasis.
• Baseline Investigator's Global Assessment Score of 3 (moderate).
• Subjects must have a Body Surface Area (BSA) between 2% to 20%
• Females of child bearing potential (excluding women who are surgically sterilized (tubal ligation or bilateral oophorectomy or hysterectomy) or post-menopausal for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day1(Baseline), must be willing to use an acceptable form of birth control during the study.

Exclusion criteria

• Pregnant, breastfeeding or planning a pregnancy within the period of their study participation period.
• Current diagnosis of unstable forms of psoriasis in the treatment area.
• History of unresponsiveness to topical treatment for psoriasis
• Presence of any other skin condition that, in the Investigator's opinion, might interfere with psoriasis diagnosis and/or evaluations
• Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments
• Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study
• Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
• Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study